BETA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 44/100 — Quality 55 · Valuation 0 · Momentum 89
| Share price | ₹2,439.40 |
| Market cap | ₹2,389 Cr |
| P/E ratio | 57.8 |
| P/B ratio | 9.8 |
| ROCE | 18.0% |
| Book value | ₹241.55 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹385 Cr | ₹41 Cr | 20.0% |
| 2025 | ₹362 Cr | ₹42 Cr | 21.0% |
| 2024 | ₹296 Cr | ₹36 Cr | 20.0% |
| 2023 | ₹227 Cr | ₹31 Cr | 23.0% |
| 2022 | ₹184 Cr | ₹25 Cr | 23.0% |
Beta Drugs Limited develops, manufactures, and sells anti-cancer bulk drugs and finished dosages in India. The company offers cosmeceutical and oncology products. It also manufactures active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). The company exports its products. Beta Drugs Limited was founded in 1985 and is based in Panchkula, India.